Upgrade to SI Premium - Free Trial

Brainstorm Cell Therapeutics (BCLI) Reports Expanded Manufacturing of NurOwn for Phase 2 Progressive MS Trial

December 26, 2018 5:44 AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced today that it has expanded its autologous cell manufacturing capacity to produce NurOwn® ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Management Comments

Next Articles